{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:29:21Z","timestamp":1788262161185,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,3,13]],"date-time":"2017-03-13T00:00:00Z","timestamp":1489363200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s00432-017-2372-z","type":"journal-article","created":{"date-parts":[[2017,3,13]],"date-time":"2017-03-13T04:03:20Z","timestamp":1489377800000},"page":"1167-1176","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries"],"prefix":"10.1007","volume":"143","author":[{"given":"Jan","family":"Geissler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giora","family":"Sharf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Bombaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Daban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"De Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Gavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Pelouchova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euzebiusz","family":"Dziwinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Hasford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena Sophia","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,13]]},"reference":[{"issue":"6","key":"2372_CR1","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6): 872\u2013884","journal-title":"Blood"},{"issue":"2","key":"2372_CR2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3324\/haematol.2013.094045","volume":"99","author":"M Baccarani","year":"2014","unstructured":"Baccarani M, Efficace F, Rosti G (2014) Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden. Haematologica 99(2):205\u2013208","journal-title":"Haematologica"},{"issue":"4","key":"2372_CR3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0149-2918(98)80139-2","volume":"20","author":"R Balkrishnan","year":"1998","unstructured":"Balkrishnan R (1998) Predictors of medication adherence in the elderly. Clin Ther 20(4):8","journal-title":"Clin Ther"},{"issue":"10","key":"2372_CR4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijnurstu.2008.02.009","volume":"45","author":"M Banning","year":"2008","unstructured":"Banning M (2008) Older people and adherence with medication: a review of the literature. Int J Nurs Stud 45(10):11","journal-title":"Int J Nurs Stud"},{"issue":"10","key":"2372_CR5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0895-4356(98)00066-3","volume":"51","author":"R Bender","year":"1998","unstructured":"Bender R, Grouven U (1998) Using binary logistic regression models for ordinal data with non-proportional odds. J Clin Epidemiol 51(10):7","journal-title":"J Clin Epidemiol"},{"issue":"18","key":"2372_CR6","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","volume":"29","author":"M Bjorkholm","year":"2011","unstructured":"Bjorkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sjoberg J et al (2011) Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 29(18): 2514\u20132520","journal-title":"J Clin Oncol"},{"issue":"6","key":"2372_CR7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00019053-200725060-00004","volume":"25","author":"T Darkow","year":"2007","unstructured":"Darkow T, Henk H, Thomas S, Feng W, Baladi J, Goldberg G et al (2007) Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 25(6):15","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"2372_CR30","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S0895-4356(01)00457-7","volume":"54","author":"J Dunbar-Jacob","year":"2001","unstructured":"Dunbar-Jacob J, Mortimer-Stephens MK (2001) Treatment adherence in chronic disease. J Clin Epidemiol 54(12):S57\u2013S60","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"2372_CR8","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1200\/JCO.2013.52.9123","volume":"32","author":"SB Dusetzina","year":"2014","unstructured":"Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL (2014) Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 32(4): 306\u2013311.","journal-title":"J Clin Oncol"},{"issue":"17","key":"2372_CR9","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","volume":"118","author":"F Efficace","year":"2011","unstructured":"Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F et al (2011) Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 118(17): 4554\u20134560","journal-title":"Blood"},{"issue":"6","key":"2372_CR10","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/bjc.2012.348","volume":"107","author":"F Efficace","year":"2012","unstructured":"Efficace F, Baccarani M, Rosti G, Cottone F, Castagnetti F, Breccia M et al (2012) Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer 107(6):904\u2013909","journal-title":"Br J Cancer"},{"issue":"5","key":"2372_CR11","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.leukres.2010.10.017","volume":"35","author":"L Eliasson","year":"2011","unstructured":"Eliasson L, Clifford S, Barber N, Marin D (2011) Exploring chronic myeloid leukemia patients\u2019 reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res 35(5): 626\u2013630","journal-title":"Leuk Res"},{"issue":"1","key":"2372_CR12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.amjopharm.2011.02.004","volume":"9","author":"WF Gellad","year":"2011","unstructured":"Gellad WF, Grenard JL, Marcum ZA (2011) A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. Am J Geriatr Pharmacother 9(1):12","journal-title":"Am J Geriatr Pharmacother"},{"issue":"8","key":"2372_CR13","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/sj.leu.2403006","volume":"17","author":"R Hehlmann","year":"2003","unstructured":"Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Metzgeroth G, Maywald O et al (2003) Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. Leukemia 17(8):1529\u20131537","journal-title":"Leukemia"},{"issue":"11","key":"2372_CR14","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1182\/blood-2006-11-055186","volume":"109","author":"R Hehlmann","year":"2007","unstructured":"Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J et al (2007) Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 109(11): 4686\u20134692","journal-title":"Blood"},{"issue":"12","key":"2372_CR15","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","volume":"29","author":"R Hehlmann","year":"2011","unstructured":"Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Muller MC, Pletsch N et al (2011) Tolerability-adapted imatinib 800\u00a0mg\/d versus 400\u00a0mg\/d versus 400\u00a0mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 29(12): 1634\u20131642","journal-title":"J Clin Oncol"},{"key":"2372_CR16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/1477-7525-11-167","volume":"11","author":"I Hirji","year":"2013","unstructured":"Hirji I, Gupta S, Goren A, Chirovsky DR, Moadel AB, Olavarria E et al (2013) Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient\u2019s perspective. Health Qual Life Outcomes 11:167","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"2372_CR17","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","volume":"29","author":"VS Hoffmann","year":"2015","unstructured":"Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D et al (2015) The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia 29(6):1336\u20131343","journal-title":"Leukemia"},{"issue":"7","key":"2372_CR18","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood-2013-04-495598","volume":"122","author":"M Hoglund","year":"2013","unstructured":"Hoglund M, Sandin F, Hellstrom K, Bjoreman M, Bjorkholm M, Brune M et al (2013) Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood 122(7): 1284\u20131292.","journal-title":"Blood"},{"key":"2372_CR19","unstructured":"Howlader N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse S et al (2015) SEER cancer statistics review, 1975\u20132012. National Cancer Institute, Bethesda, MD. \nhttp:\/\/seer.cancer.gov\/csr\/1975_2012\/"},{"issue":"4","key":"2372_CR20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000126073","volume":"77","author":"EA Joosten","year":"2008","unstructured":"Joosten EA, DeFuentes-Merillas L, De Weert G, Sensky T, Van Der Staak C, de Jong CA (2008) Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status. Psychother Psychosom 77(4):219\u2013226","journal-title":"Psychother Psychosom"},{"issue":"1","key":"2372_CR21","doi-asserted-by":"crossref","first-page":"e2015013","DOI":"10.4084\/mjhid.2015.013","volume":"7","author":"J Kapoor","year":"2015","unstructured":"Kapoor J, Agrawal N, Ahmed R, Sharma SK, Gupta A, Bhurani D (2015) Factors influencing adherence to imatinib in indian chronic myeloid leukemia patients: a cross-sectional study. Mediterr J Hematol Infect Dis 7(1): e2015013","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2372_CR22","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2147\/PPA.S70712","volume":"8","author":"M Kekale","year":"2014","unstructured":"Kekale M, Talvensaari K, Koskenvesa P, Porkka K, Airaksinen M (2014) Chronic myeloid leukemia patients\u2019 adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians. Patient Preference Adherence 8:1619\u20131627","journal-title":"Patient Preference Adherence"},{"key":"2372_CR23","unstructured":"Le CT (1998) Applied categorical data analysis. Wiley, New York"},{"issue":"14","key":"2372_CR24","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M et al (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28(14):2381\u20132388","journal-title":"J Clin Oncol"},{"issue":"5","key":"2372_CR25","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1751-7176.2008.07572.x","volume":"10","author":"DE Morisky","year":"2008","unstructured":"Morisky DE, Ang A, Krousel-Wood M, Ward HJ (2008) Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens 10(5):348\u2013354","journal-title":"J Clin Hypertens"},{"issue":"22","key":"2372_CR26","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","volume":"113","author":"L Noens","year":"2009","unstructured":"Noens L, van Lierde MA, De Bock R, Verhoef G, Zachee P, Berneman Z et al (2009) Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113(22): 5401\u20135411","journal-title":"Blood"},{"issue":"3","key":"2372_CR27","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.2012.082511","volume":"99","author":"L Noens","year":"2014","unstructured":"Noens L, Hensen M, Kucmin-Bemelmans I, Lofgren C, Gilloteau I, Vrijens B (2014) Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges. Haematologica 99(3): 437\u2013447","journal-title":"Haematologica"},{"key":"2372_CR28","volume-title":"Adherence to long-term therapies: evidence for action","author":"E Sabat\u00e9","year":"2003","unstructured":"Sabat\u00e9 E (2003) Adherence to long-term therapies: evidence for action. WHO Library Cataloguing-in-Publication Data, Geneva"},{"issue":"5","key":"2372_CR29","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1046\/j.1365-2710.2001.00363.x","volume":"26","author":"E Vermeire","year":"2001","unstructured":"Vermeire E, Hearnshaw H, Van Royen P, Denekens J (2001) Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 26(5):331\u2013342","journal-title":"J Clin Pharm Ther"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-017-2372-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2372-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2372-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T14:36:27Z","timestamp":1498142187000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-017-2372-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,13]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["2372"],"URL":"https:\/\/doi.org\/10.1007\/s00432-017-2372-z","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,13]]}}}